A study looking at the impact of pneumococcal vaccine introduction and scaling up pneumonia treatment in Ethiopia found that 30-40% of all deaths averted by these interventions would be expected to occur in the poorest wealth quintile. The greatest resulting financial risk protection would also be concentrated among the bottom income quintile.
Full Citation:
Johannsen, K.A, Memirie, S.T., Pecenka, C. et al. 2015. Health gains and financial protection from pneumococcal vaccination and pneumonia treatment in Ethiopia: Results from an extended cost-effectiveness analysis. PLOS ONE. 10(12).
Title of Article: Health gains and financial protection from pneumococcal vaccination and pneumonia treatment in Ethiopia: Results from an extended cost-effectiveness analysis
Author(s): Johannsen, K.A, Memirie, S.T., Pecenka, C. et al
Publication Year: 2015
Publication Name: PLOS ONE
Publication Volume: 10(12)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674114/
DOI (Digital Object Identifier): 10.1371/journal.pone.0142691
Topics: Equity
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: Ethiopia
WHO Regions: Africa